Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04434196 · ClinicalTrials.gov registry record · Phase 1
A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Phase 1 study of Lymphoma, Non-Hodgkin, sponsored by Celgene.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 15
- Study locations
NCT04434196 is a Phase 1 study of Lymphoma, Non-Hodgkin that has completed, run by Celgene. The registered enrollment target is 16 participants, below the 394-participant average among 56 other Lymphoma, Non-Hodgkin trials with a reported enrollment target (96% lower). The trial reports 15 study locations across 8 states.
The verdict
NCT04434196, a Phase 1 study of Lymphoma, Non-Hodgkin, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 15
- Study locations
Study Summary
CC-99282-CLL-001 study is a Phase IB dose escalation and expansion clinical study of CC-99282 administered in combination with Obinutuzumab in subjects with relapsed or refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Conditions Studied
Interventions
- DRUG Obinutuzumab
- DRUG CC-99282
Study Locations (15)
Other
- Local Institution - 403 - Innsbruck
- Local Institution - 401 - Salzburg
- Local Institution - 402 - Vienna
- Local Institution - 302 - Barcelona
- Local Institution - 306 - Madrid
- Local Institution - 301 - Madrid
- Local Institution - 303 - Salamanca
- Local Institution - 305 - Valencia
Massachusetts
- Local Institution - 106 - Boston
Ohio
- Local Institution - 104 - Columbus
Oregon
- Local Institution - 101 - Portland
Texas
- Local Institution - 107 - Dallas
Ontario
- Local Institution - 201 - Toronto
Quebec
- Local Institution - 202 - Montreal
Navarre
- Local Institution - 304 - Pamplona
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2020-12-21 |
| Est. Completion | 2024-05-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04434196
The ClinicalTrials.gov registry entry for NCT04434196 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 394-participant average among 56 other Lymphoma, Non-Hodgkin trials with a reported enrollment target (96% lower). The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lymphoma, Non-Hodgkin appearing as the primary indexed condition, and to 2 interventions - of which Obinutuzumab is the first listed.
NCT04434196 reports 15 study locations spanning 8 distinct geographic areas - top geographies include Other, Massachusetts, Ohio.
Frequently Asked Questions
What is clinical trial NCT04434196 about?
NCT04434196 is a clinical study titled "A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma". CC-99282-CLL-001 study is a Phase IB dose escalation and expansion clinical study of CC-99282 administered in combination with Obinutuzumab in subjects with relapsed or refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
What is the current status of trial NCT04434196?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2020-12-21. Estimated completion is 2024-05-21.
What conditions does trial NCT04434196 study?
This clinical trial studies the following conditions: Lymphoma, Non-Hodgkin.
What interventions are being tested in trial NCT04434196?
The interventions under investigation include: Obinutuzumab (DRUG), CC-99282 (DRUG).
Who is sponsoring clinical trial NCT04434196?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04434196 being conducted?
This trial has 15 study locations across Massachusetts, Ohio, Oregon, Texas, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma, Non-Hodgkin
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
RECRUITING · Phase 1
-
Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.